An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Vyndaqel

Chemical Nametafamidis meglumine
Dosage FormCapsule (oral; 20 mg)
Drug ClassMiscellaneous
SystemCardiovascular
CompanyFoldRx Pharmaceuticals
Approval Year2019

Indication

  • Vyndaqel is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
Last updated on 10/20/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Vyndaqel (tafamidis meglumine) Prescribing Information2019Pfizer
Document TitleYearSource
Clinical review report: tafamidis (vyndaqel) (Pfizer).2020CADTH
Pharamacoeconomic review report: tafamidis (vyndaqel) (Pfizer).2020CADTH
Swiss public assessment report: vyndaqel.2020Swiss Medic
Document TitleYearSource
Pharmacological treatment for familial amyloid polyneuropathy.2020Cochrane Database of Systematic Reviews.
Specific therapy for transthyretin cardiac amyloidosis: a systematic literature review and evidence‐based recommendations.2020Journal of the American Heart Association